H.C. Wainwright analysts on Tuesday maintained their $145 price target and Buy rating for Corcept Therapeutics Incorporated (NASDAQ:CORT), reflecting a significant upside potential from its current trading level of $69.51 per share.
A biologist in a lab coat studying a culture of cells to find a cure for metabolic disorders.
The reaffirmation followed Corcept Therapeutics Incorporated’s detailed presentation on its Phase 3 ROSELLA trial at the ASCO 2025 Annual Meeting.
The study is evaluating the efficacy of relacorilant combined with nab-paclitaxel in patients with platinum-resistant ovarian cancer. Corcept Therapeutics Incorporated said the trial met its primary endpoint of improved progression-free survival, with patients experiencing a 30% reduction in the risk of disease progression, compared to those receiving nab-paclitaxel monotherapy.
H.C. Wainwright analysts noted the significance of these findings and decided to maintain their price target and rating for the stock.
Corcept Therapeutics Incorporated is a commercial-stage company engaged in the discovery and development of treatments for severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol.
READ NEXT: ChatGPT Stock Advice: Top 12 Stock Recommendations and 10 Cheap Rising Stocks to Buy Right Now.
